OKYO - יחס חוב להיוון בספרים okyopharma.com

The prospects for OKYO Pharma Limited are bolstered by the potential to capture the commercial sector following FDA certification, which is driving price action. The debt-to-equity ratio is currently fixed at 0.00. The business foundation is based on the development of non-peptide antagonists to combat corneal inflammation, while the growth strategy focuses on eliminating the root causes of ophthalmological pain.

Investors are assessing the financial stability of OKYO Pharma Limited through the lens of its debt load. This metric is calculated as the ratio of total liabilities to net asset value, identifying the risk of a "value trap." This chart of the total debt-to-book capitalization ratio captures a value of 0.00. For an ophthalmology startup without its own manufacturing plants, this indicator is critical. A low debt load confirms the company's ability to fund clinical trials without the risk of capital freezes.